Journal of Gastrointestinal Oncology

Aims & Scope

ournal of Gastrointestinal Oncology (Print ISSN 2078-6891; Online ISSN 2219-679X; J Gastrointest Oncol; JGO), the official journal of Society for Gastrointestinal Oncology (SGO), is an open-access, international peer-reviewed journal.

It is published quarterly (Sep. 2010- Dec. 2013), bimonthly (Feb. 2014 -) and openly distributed worldwide.

JGO publishes manuscripts that focus on updated and practical information about diagnosis, prevention and clinical investigations of gastrointestinal cancer treatment.

Specific areas of interest include, but not limited to, multimodality therapy, markers, imaging and tumor biology.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2
2024	2.00

SJR (SCImago Journal Rank)

Year	Value
2024	0.687

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	60

Journal Rank

Year	Value
2024	8287

Journal Citation Indicator

Year	Value
2024	1760

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy

  Citation: 266

  Authors: Dae Won, Chetasi, Richard

• Gastrointestinal stromal tumors: a comprehensive review

  Citation: 222

  Authors: Trisha M., Michael J., Alexander M., Salvatore A., Paul S., David A., Olivier, Saloomeh, Jian-Hua, Gudata S.

• Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition

  Citation: 216

  Authors: David A., Thomas J., Richard F., Garrett, James, Kyle, Mark, Joel, Alexa B., Aram F., Jeffrey S., Phillip J., Siraj M., Vincent A., Marwan, Samuel J.

• Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review

  Citation: 160

  Authors: Audra N., Catherine, Robin Kate

• Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management

  Citation: 158

  Authors: Hrishikesh, Hosein Shokouh, Gazi B.

• The gut microbiome and colorectal cancer: a review of bacterial pathogenesis

  Citation: 147

  Authors: Jessica D., Drew L., David M., C. Andrew

• Updates on immunotherapy for colorectal cancer

  Citation: 143

  Authors: Aparna, Sheetal, Hiral, Mary, Al

• Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets

  Citation: 143

  Authors: Benjamin A., Joanne, Michael R., Anthony F., Jimmy J., Kelsey, Mohamed E., Michael J., Randall F., John L., Michael A.

• Hepatic metastasis from colorectal cancer

  Citation: 141

  Authors: Alfred Wei Chieh

• Systematic review and a meta-analysis of hospital and surgeon volume/outcome relationships in colorectal cancer surgery

  Citation: 135

  Authors: Ya Ruth, Kevin, David L., Winston

---